The University of Maryland has launched a new clinical trial testing a novel
treatment for patients with localized, inoperable recurrent squamous cell carcinoma
of the head and neck. The treatment employs the immunotherapy drug
MK-3475 (Pembrolizumab) in combination with radiation to the tumor, and
is indicated for patients who have received prior radiation, have no
evidence of distant metastatic disease and for whom surgery is not an
option.
The national trial is being led by Dan P. Zandberg, MD, assistant professor of medicine at the University of Maryland School of Medicine
and a medical oncologist specializing in head and neck cancers at
UMGCC. The Greenebaum Cancer Center is currently the only trial site and
is actively recruiting participants.
“When surgery isn’t possible for patients with locally recurrent
squamous cell carcinoma of the head and neck, unfortunately, prognosis
is generally poor, and newer more effective treatments are greatly
needed.” says Dr. Zandberg. “MK-3475 has shown promise for treating head
and neck cancers in clinical trials, and it’s our hope that it will
prove to be even more effective against this type of cancer when given
in combination with radiation.”
MK-3475 is one in a promising new class of immunotherapy cancer drugs
that work by activating a patient’s own immune system against the
tumor. Cancer cells thrive in part by suppressing the immune system so
the immune system cannot attack the tumor. One important way the immune
system is suppressed is by the interaction between PD-L1 on cancer cells
and PD-1 on T cells—a type of white blood cell that is part of the
immune system. PD-L1 (Programmed death ligand 1) is expressed by cancer
cells and binds to PD-1 (Programmed death 1) on T cells, causing them
to stop attacking the cancer. MK-3475 is a man-made antibody against
PD-1 and blocks this interaction, allowing the T cells to continue to
attack the cancer.
MK-3475 is approved by the U.S. Food and Drug Administration for
treatment of advanced melanoma. It is being tested by its maker,
pharmaceutical company Merck,
for treatment of multiple different cancers including head and neck,
kidney and lung cancer. In head and neck cancer preliminary efficacy has
led to the development of a larger phase III trial for patients with
advanced squamous cell carcinoma of the head and neck.
The UMGCC trial is the first to use MK-3475 in combination with
radiation therapy to treat any type of cancer. By combining the drug
with radiation, which is known to stimulate the immune system,
researchers believe that, in addition to its local effects against the
tumor, the radiation will increase the efficacy of MK-3475 and this
synergy will result in improved outcomes for patients with inoperable
localized recurrence of their head and neck cancer. Merck is providing
the drug and funding for the trial.
The vast majority of cancers in the head and neck are squamous cell
carcinomas. When patients are first diagnosed, treatment is typically
up-front surgery or combined radiation and chemotherapy. Patients who
undergo up-front surgery may receive radiation or combined radiation and
chemotherapy after the surgery. Thus a significant amount of patients
receive radiation as part of their initial therapy. If these patients
recur without evidence of distant metastatic disease (cancer spreading
beyond the head and neck) and surgical resection is not an option, they
are typically treated with radiation again (reirradiation) combined with
chemotherapy. Improved outcomes are needed for these patients, as
unfortunately, the median progression-free survival is only 7-8 months.
The primary endpoint of the trial is to determine if progression-free
survival is extended by treatment with reirradiation and MK-3475.
Forty-eight patients will be recruited for the trial. All patients
will receive radiation twice per day for five weeks with MK-3475 given
intravenously every three weeks starting on the first day of radiation.
MK-3475 will be continued for an additional three months following the
completion of reirradiation. Patients will then be evaluated for
response in their tumor. If there is a complete response, MK-3475 will
be stopped and the patient will be followed to see if the tumor recurs.
If there is a partial response or stable disease, the patient will
continue being treated with MK-3475 as long as the tumor continues to
respond or stay stable in size. If the tumor progresses, treatment with
MK-3475 will be discontinued. Toxicity will be monitored closely during
this trial.
To learn more about participating in this trial, read the frequently asked questions on the UMGCC website.